144 related articles for article (PubMed ID: 19691482)
1. P-selectin antagonism reduces thrombus formation in humans.
Chelliah R; Lucking AJ; Tattersall L; Daga S; Beresford-Cleary NJ; Cortas K; Fox KA; Feuerstein GZ; Connolly TM; Newby DE
J Thromb Haemost; 2009 Nov; 7(11):1915-9. PubMed ID: 19691482
[TBL] [Abstract][Full Text] [Related]
2. Effects of GP IIb/IIIa receptor inhibitor tirofiban (aggrastat) in ex vivo canine arteriovenous shunt model of stent thrombosis.
Rukshin V; Azarbal B; Finkelstein A; Shah PK; Cercek B; Tsang V; Kaul S
J Cardiovasc Pharmacol; 2003 Apr; 41(4):615-24. PubMed ID: 12658064
[TBL] [Abstract][Full Text] [Related]
3. Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis.
Rukshin V; Shah PK; Cercek B; Finkelstein A; Tsang V; Kaul S
Circulation; 2002 Apr; 105(16):1970-5. PubMed ID: 11997285
[TBL] [Abstract][Full Text] [Related]
4. Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth. An ex vivo capillary perfusion chamber study in the guinea pig.
André P; Arbeille B; Drouet V; Hainaud P; Bal dit Sollier C; Caen JP; Drouet LO
Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):56-63. PubMed ID: 8548427
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition.
Meah MN; Raftis J; Wilson SJ; Perera V; Garonzik SM; Murthy B; Everlof JG; Aronson R; Luettgen J; Newby DE
Arterioscler Thromb Vasc Biol; 2020 Nov; 40(11):2678-2685. PubMed ID: 32907366
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist.
Ahmad S; Jeske WP; Ma Q; Walenga JM; Fareed J
Thromb Res; 2001 Apr; 102(2):143-51. PubMed ID: 11323025
[TBL] [Abstract][Full Text] [Related]
7. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.
Goto S; Tamura N; Li M; Handa M; Ikeda Y; Handa S; Ruggeri ZM
J Thromb Haemost; 2003 Sep; 1(9):2022-30. PubMed ID: 12941046
[TBL] [Abstract][Full Text] [Related]
8. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial.
Derhaschnig U; Pachinger C; Jilma B
Am Heart J; 2004 Apr; 147(4):E17. PubMed ID: 15077100
[TBL] [Abstract][Full Text] [Related]
9. Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis.
Wilson SJ; Connolly TM; Peters G; Ghosh A; Johnson M; Newby DE
Cardiovasc Res; 2019 Mar; 115(3):669-677. PubMed ID: 30184110
[TBL] [Abstract][Full Text] [Related]
10. Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils.
Caron A; Théorêt JF; Mousa SA; Merhi Y
J Cardiovasc Pharmacol; 2002 Aug; 40(2):296-306. PubMed ID: 12131559
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of shear-stress-induced platelet aggregation and phosphotyrosine signaling by GPIIb-IIIa antagonists.
Haga JH; Jennings LK; Slack SM
Ann Biomed Eng; 2002; 30(10):1262-72. PubMed ID: 12540202
[TBL] [Abstract][Full Text] [Related]
12. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
Zhao XQ; Théroux P; Snapinn SM; Sax FL
Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731
[TBL] [Abstract][Full Text] [Related]
13. Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans.
Japp AG; Chelliah R; Tattersall L; Lang NN; Meng X; Weisel K; Katz A; Burt D; Fox KA; Feuerstein GZ; Connolly TM; Newby DE
J Am Heart Assoc; 2013 Jan; 2(1):e006007. PubMed ID: 23525448
[TBL] [Abstract][Full Text] [Related]
14. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
[TBL] [Abstract][Full Text] [Related]
15. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD
Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143
[TBL] [Abstract][Full Text] [Related]
16. Prevention of microsurgical anastomotic thrombosis using aspirin, heparin, and the glycoprotein IIb/IIIa inhibitor tirofiban.
Chung TL; Pumplin DW; Holton LH; Taylor JA; Rodriguez ED; Silverman RP
Plast Reconstr Surg; 2007 Oct; 120(5):1281-1288. PubMed ID: 17898601
[TBL] [Abstract][Full Text] [Related]
17. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis.
Makkar RR; Litvack F; Eigler NL; Nakamura M; Ivey PA; Forrester JS; Shah PK; Jordan RE; Kaul S
Circulation; 1997 Feb; 95(4):1015-21. PubMed ID: 9054765
[TBL] [Abstract][Full Text] [Related]
18. [Different inhibiting effects of abciximab and tirofiban on platelet thrombus formation on a collagen surface under flow conditions].
Shimazaki T; Goto S; Sakakibara M; Eto K; Kim JY; Ichikawa N; Yoshida M; Nagaoka Y; Isshiki T; Handa S
J Cardiol; 2000 Aug; 36(2):113-21. PubMed ID: 10955255
[TBL] [Abstract][Full Text] [Related]
19. Shear-dependent suppression of platelet thrombus formation by phosphodiesterase 3 inhibition requires low levels of concomitant Gs-coupled receptor stimulation.
Yoshida H; Okamura Y; Watanabe N; Ikeda Y; Handa M
Thromb Haemost; 2011 Mar; 105(3):487-95. PubMed ID: 21136009
[TBL] [Abstract][Full Text] [Related]
20. Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermic circulatory arrest.
Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
Thromb Haemost; 2005 Jul; 94(1):115-22. PubMed ID: 16113794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
